| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… |
Trial completed |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… |
Enrollment reduced: 20 -> 5 participants |
| 2026-08-15 | NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in… |
date change Primary completion pushed: 2025-07-07 -> 2026-06-30 |
| 2026-08-12 | NCT06719856 MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors |
Recruitment opened |
| 2026-08-01 | NCT07724535 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-04 | NCT07745322 Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer | Active, Not Recruiting | |
| 2026-07-24 | NCT07724535 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy | Phase 1/2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07344974 | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity | Breast Cancer | Not Yet Recruiting |
| NCT07599137 | Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy | HR+/HER2- Breast Cancer | Not Yet Recruiting |
| Phase 3 | |||
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in… | Acral Melanoma | Recruiting |
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer… | Rectal Cancer | Recruiting |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients… | Renal Cell Carcinoma (RCC) | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for… | Rectal Cancer | Not Yet Recruiting |
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT05104788 | A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm… | Non-Small Cell Lung Cancer | Recruiting |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or… | Unresectable Hepatocellular Carcinoma | Recruiting |
| NCT05985109 | KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | Colorectal Cancer | Recruiting |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to… | Digestive System Cancers | Recruiting |
| NCT06141265 | Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line… | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Recruiting |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for… | Unresectable Hepatocellular Carcinoma | Recruiting |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | Ovarian Carcinoma | Recruiting |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced… | Collecting Duct Carcinoma | Recruiting |
| NCT06849167 | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by… | Non-Small Cell Lung Cancer | Recruiting |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | Melanoma | Recruiting |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus… | NK/T Cell Lymphoma | Recruiting |
| NCT06992362 | Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach | Hepatoid Adenocarcinoma of Stomach | Recruiting |
| NCT06869213 | A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in… | Esophageal Cancer (EsC) | Recruiting |
| NCT06869226 | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination… | Esophageal Cancer | Recruiting |
| NCT07178340 | Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach | Hepatoid Adenocarcinoma of Stomach | Recruiting |
| NCT05985707 | KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | HER2-positive Colorectal Cancer | Not Yet Recruiting |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical… | Thrombopenia | Not Yet Recruiting |
| NCT06768307 | Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus… | SCLC, Extensive Stage | Not Yet Recruiting |